HB-086
Neuropathic pain (CIPN, Trigeminal Neuralgia)
PreclinicalActive
Key Facts
Indication
Neuropathic pain (CIPN, Trigeminal Neuralgia)
Phase
Preclinical
Status
Active
Company
About Hoba Therapeutics
Hoba Therapeutics is a private, preclinical-stage biotech leveraging a novel platform of endogenous neurotrophic proteins, meteorin and cometin, to develop restorative treatments for sensory neuron disorders. Its lead program, HB-086, targets neuropathic pain (CIPN and trigeminal neuralgia) and is in late preclinical development, while HB-097 targets ototoxic hearing loss in preclinical stages. The company is backed by notable investors like Novo Holdings and Eir Ventures, having recently raised a €23 million Series A round in late 2023 to advance its pipeline.
View full company profile